BGT 007
Alternative Names: BGT-007; BGT007HLatest Information Update: 05 Jul 2024
At a glance
- Originator BioSyngen
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Digestive system neoplasms; Gastrointestinal cancer; Nasopharyngeal cancer
- Clinical Phase Unknown Pancreatic cancer
- Preclinical Colorectal cancer; Oesophageal cancer
Most Recent Events
- 07 May 2024 Clinical trials in Pancreatic cancer (Second-line therapy or greater, Late-stage disease) in China (Parenteral) (NCT06478225)
- 22 Oct 2023 Phase-0 for Digestive system neoplasms (Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT06104215)
- 22 Oct 2023 Guangzhou Bioresette Biomedical Technology initiates a phase 0 trial for Digestive system neoplasms (Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06104241)